D Mischoulon

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. Mischoulon D, Price L, Carpenter L, Tyrka A, Papakostas G, Baer L, et al. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry. 2014;75:370-6 pubmed publisher
    ..05 for all). The results fail to support an advantage over placebo for either the investigational treatment SAMe or the standard treatment escitalopram for MDD. ClinicalTrials.gov identifier: NCT00101452. ..
  2. Mischoulon D, Shelton R, Baer L, Bobo W, Curren L, Fava M, et al. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2017;78:449-455 pubmed publisher
    ..ClinicalTrials.gov identifier: NCT00633399​​. ..
  3. Mischoulon D, Hylek L, Yeung A, Clain A, Baer L, Cusin C, et al. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord. 2017;208:6-14 pubmed publisher
    ..3±0.5 to 4.0±0.6 for placebo (d=1.22; p=0.064). Small study; restrictions on allowed antidepressants. LDN augmentation showed some benefit for MDD relapse on dopaminergic agents. Confirmation in larger studies is needed. ..

Detail Information

Publications3

  1. Mischoulon D, Price L, Carpenter L, Tyrka A, Papakostas G, Baer L, et al. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry. 2014;75:370-6 pubmed publisher
    ..05 for all). The results fail to support an advantage over placebo for either the investigational treatment SAMe or the standard treatment escitalopram for MDD. ClinicalTrials.gov identifier: NCT00101452. ..
  2. Mischoulon D, Shelton R, Baer L, Bobo W, Curren L, Fava M, et al. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2017;78:449-455 pubmed publisher
    ..ClinicalTrials.gov identifier: NCT00633399​​. ..
  3. Mischoulon D, Hylek L, Yeung A, Clain A, Baer L, Cusin C, et al. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord. 2017;208:6-14 pubmed publisher
    ..3±0.5 to 4.0±0.6 for placebo (d=1.22; p=0.064). Small study; restrictions on allowed antidepressants. LDN augmentation showed some benefit for MDD relapse on dopaminergic agents. Confirmation in larger studies is needed. ..